Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo
- PMID: 3257705
- DOI: 10.1016/0167-4889(88)90005-5
Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo
Abstract
The therapeutic activity of ricin A-chain immunotoxins is undermined by their rapid clearance from the bloodstream of animals by the liver. This uptake has generally been attributed to recognition of the mannose-terminating oligosaccharides present on ricin A-chain by receptors present on the non-parenchymal (Kupffer and sinusoidal) cells of the liver. However, we demonstrate here that, in the mouse, the liver uptake of a ricin A-chain immunotoxin occurs in both parenchymal and non-parenchymal cells in equal amounts. This is in contrast to the situation in the rat, where uptake of the immunotoxin is predominantly by the non-parenchymal cells. Recognition of sugar residues on the A-chain portion of the immunotoxin plays an important role in the liver uptake by both cell types in both species. However it is not the only mechanism since, firstly, an immunotoxin containing ricin A-chain which had been effectively deglycosylated with metaperiodate and cyanoborohydride was still trapped to a significant extent by hepatic non-parenchymal cells after it was injected into mice. Secondly, deglycosylation, while eliminating uptake of the free A-chain by parenchymal and non-parenchymal cells in vitro, only reduced the uptake of an immunotoxin by either cell type by about half. Thirdly, the addition of excess D-mannose or L-fucose inhibited the uptake of free A-chain by mouse liver cell cultures by more than 80% but only inhibited the uptake of the native A-chain immunotoxin by about half and had little effect on the uptake of the deglycosylated ricin A-chain immunotoxin. Recognition of the antibody portion of the immunotoxin by liver cells seems improbable, since antibody alone or an antibody-bovine serum albumin conjugate were not taken up in appreciable amounts by the cultures. Possibly attachment of the A-chain to the antibody exposes sites on the A-chain that are recognised by liver cells in vitro and in vivo.
Similar articles
-
Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.Cancer Res. 1987 Feb 15;47(4):947-52. Cancer Res. 1987. PMID: 3492271
-
Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.Cancer Res. 1988 Dec 15;48(24 Pt 1):7072-8. Cancer Res. 1988. PMID: 3263899
-
The low uptake of an abrin A-chain immunotoxin by rat hepatic cells in vivo and in vitro.Cancer Lett. 1989 Aug;46(3):161-6. doi: 10.1016/0304-3835(89)90125-0. Cancer Lett. 1989. PMID: 2788492
-
Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver.Cancer Treat Res. 1988;37:457-73. doi: 10.1007/978-1-4613-1083-9_25. Cancer Treat Res. 1988. PMID: 2908639 Review. No abstract available.
-
Toxin selection and modification: utilization of the A chain of ricin.Cancer Treat Res. 1988;37:97-111. doi: 10.1007/978-1-4613-1083-9_7. Cancer Treat Res. 1988. PMID: 2908645 Review. No abstract available.
Cited by
-
Therapeutic strategies with monoclonal antibodies and immunoconjugates.Immunology. 1988 Nov;65(3):329-35. Immunology. 1988. PMID: 3061932 Free PMC article. Review. No abstract available.
-
Bacterial Toxins for Cancer Therapy.Toxins (Basel). 2017 Jul 28;9(8):236. doi: 10.3390/toxins9080236. Toxins (Basel). 2017. PMID: 28788054 Free PMC article. Review.
-
Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target.J Pharmacokinet Biopharm. 1993 Feb;21(1):75-98. doi: 10.1007/BF01061776. J Pharmacokinet Biopharm. 1993. PMID: 8410684
-
Clinical targeting recombinant immunotoxins for cancer therapy.Onco Targets Ther. 2017 Jul 20;10:3645-3665. doi: 10.2147/OTT.S134584. eCollection 2017. Onco Targets Ther. 2017. PMID: 28790855 Free PMC article. Review.
-
Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.Cancer Immunol Immunother. 1995 Dec;41(6):331-8. doi: 10.1007/BF01526552. Cancer Immunol Immunother. 1995. PMID: 8635190 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources